AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32343001
Drug: Non-alginate antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-alginate antacid
Trial: 33577055
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg twice daily for 12 weeks)
Trial: 34408055
Drug: Solution-focused brief
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution-focused brief therapy, up to six sessions over 3 months, offered immediately postrandomisation or after a delay of 6 months.
Trial: 35507735
Drug: Bone grafting
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone grafting to buccal bone crest (BCG)
Trial: 33153273
Drug: Financial hardship
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Financial hardship treatment adherence
Trial: 33407146
Drug: Independent predictors
RxNorm normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Independent predictors for antiviral therapy
Trial: 34340839
Drug: Standard multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard multimodal analgesic regimen
Trial: 34735165
Drug: Nonmonetary reinforcers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmonetary reinforcers (e.g., delivery of meme/gif following self-reporting completion)
Trial: 34735165
Drug: Daily self-reporting
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-reporting rates
Trial: 36370991
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Psychological Intervention (PI) and Electroacupuncture (EA) 30 min, 5 times a week for 4 weeks, total of 12 weeks
Trial: 35135601
Drug: Theraflu Daytime
RxNorm normalized name: Theraflu Daytime Severe Cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theraflu Daytime Severe Cold and Cough powder for oral solution
Trial: 616463935
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec in DUAL I
Trial: 616463935
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec in DUAL II
Trial: 36479955
Drug: Pharmacotherapy following
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy following CBT
Trial: 36479955
Drug: No pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pharmacotherapy following CBT
Trial: 35318844
Drug: Mexidol intravenously,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexidol intravenously, 500 mg once daily for 14 days, followed by oral Mexidol FORTE 250, 750 mg per day for 60 days
Trial: 35318844
Drug: Mexidol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexidol treatment
Trial: 34341325
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 µg/kg for >10 min before anesthesia and during maintenance)
Trial: 33451618
Drug: Enhanced counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced counseling on optimal analgesic use
Trial: 36180905
Drug: Telehealth swallowing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth swallowing therapy sessions
Trial: 33071986
Drug: Gushen'antai pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gushen'antai pills (GSATP) 6 g, tid for 12 weeks
Trial: 33071986
Drug: Gushen'antai pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gushen'antai pills (GSATP) 6 g, tid for 12 weeks (younger than 35 years)
Trial: 32227755
Drug: Initial invasive
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial invasive strategy (angiography and revascularization when feasible) plus medical therapy
Trial: 32227755
Drug: Initial conservative
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial conservative strategy (medical therapy alone and angiography if medical therapy failed)
Trial: 35945651
Drug: 5 raw
RxNorm normalized name: Pomegranates, Raw
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 raw eggs (∼30 g protein)
Trial: 35945651
Drug: 5 boiled
RxNorm normalized name: BOIL-EASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 boiled eggs (∼30 g protein)
Trial: 35945651
Drug: Control breakfast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control breakfast (∼5 g protein)
Trial: 34262052
Drug: Microneedle patches
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedle patches (MNPs)
Trial: 34616361
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg imigliptin
Trial: 34616361
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg imigliptin
Trial: 34616361
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg alogliptin
Trial: 34632933
Drug: 120 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/day standardized cranberry extract
Trial: 34632933
Drug: 240 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg/day standardized cranberry extract
Trial: 34632933
Drug: Nitrofurantoin administration
RxNorm normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin administration
Trial: 34907082
Drug: Ipatasertib treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib treatment
Trial: 35133064
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate 0.1% (single dose)
Trial: 35133064
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate 0.1% (multiple doses, once daily for 7 days)
Trial: 35133064
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate 0.3% (single dose)
Trial: 35133064
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate 0.3% (multiple doses, once daily for 7 days)
Trial: 35133064
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (single dose)
Trial: 35133064
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (multiple doses, once daily for 7 days)
Trial: 35115339
Drug: Budesonide/formoterol 200/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 200/6 µg
Trial: 33724254
Drug: Sertraline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (100 mg/day) plus pentoxifylline (400 mg three times daily)
Trial: 33724254
Drug: Sertraline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (100 mg/day) plus placebo
Trial: 35834107
Drug: Diabetes-specific nutritional
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes-specific nutritional supplement (DSNS) plus standard of care (SOC)
Trial: 33671220
Drug: Docosahexaenoic acid
RxNorm normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docosahexaenoic acid (DHA) 75 mg/kg body weight daily for 14 days
Trial: 35293153
Drug: HFNCO (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNCO (2 L/kg/min)
Trial: 33864153
Drug: Fosfomycin-trometamol treatment
RxNorm normalized name: trometamol
DrugBank: Tromethamine (DB03754)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin-trometamol treatment for ASB (77 patients)
Trial: 35936366
Drug: Conventional antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antihypertensive therapy
Trial: 34384540
Drug: Vi‐tetanus toxoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi‐tetanus toxoid conjugate vaccine (Vi‐TT)
Trial: 34384540
Drug: SA 14‐14‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SA 14‐14‐2 Japanese encephalitis (JE) vaccine
Trial: 32799667
Drug: Electronic headache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic headache diary (daily assessment of headache presence and severity)
Trial: 32799667
Drug: Recall questionnaire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recall questionnaire (retrospective estimation of headache days on a monthly basis)
Trial: 35440935
Drug: Coriander seed
RxNorm normalized name: coriander seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coriander seed oil (CSO) 200 mg daily for 28 days
Trial: 32692755
Drug: Heart rate-reducing
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart rate-reducing genetic variant at the HCN4 locus encoding ivabradine's drug target
Trial: 33445213
Drug: Astaxanthin (AST)
DrugBank: Astaxanthin (DB06543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin (AST) supplementation, 8 mg/d for 8 weeks
Trial: 33536283
Drug: Isoniazid, pyrazinamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid, pyrazinamide, rifampicin, moxifloxacin (individual and in combination)
Trial: 33536283
Drug: Isoniazid and
RxNorm normalized name: Isoniazid and rifampin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid and pyrazinamide (combination)
Trial: 34605947
Drug: Adrecizumab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrecizumab (2 or 4 mg/kg b.w.)
Trial: 35986466
Drug: Spirulina 500
RxNorm normalized name: Spirulina 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina 500 mg twice daily along with topical triamcinolone acetonide 0.1% thrice daily for one week
Trial: 35986466
Drug: Topical triamcinolone
RxNorm normalized name: triamcinolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical triamcinolone acetonide 0.1% alone thrice daily for 8 weeks
Trial: 34982738
Drug: IV vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV vitamin C (1,000 mg bolus over 30 minutes followed by continuous infusion of 250 mg/hr for 96 hours)
Trial: 33949215
Drug: 3-month intervention
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month intervention fostering self-efficacy and social support through weekly, family-centered sessions
Trial: 34726703
Drug: GOS (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOS (15 g) with FeFum (14 mg)
Trial: 34726703
Drug: Control (FeFum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (FeFum 14 mg without GOS)
Trial: 32565594
Drug: Escitalopram 20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 20 mg daily
Trial: 33749992
Drug: Platelet gel
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet gel (PG)
Trial: 36374528
Drug: Whole tablet
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole tablet oral administration (reference formulation)
Trial: 33256796
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment for 4 weeks
Trial: 33256796
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture treatment for 4 weeks
Trial: 34090773
Drug: Dietary fiber
RxNorm normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fiber (oat bran) supplement (30 g/d, containing DF 8.9 g)
Trial: 34090773
Drug: Dietary fiber
RxNorm normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fiber (oat bran) supplement
Trial: 39678704
Drug: SQ HDM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ HDM SLIT-tablet
Trial: 34101138
Drug: 0.07 mg
RxNorm normalized name: urea 0.07 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 mg LOR
Trial: 33588087
Drug: 0.23 mg
RxNorm normalized name: morphine 0.23 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.23 mg LOR
Trial: 35099281
Drug: 80% basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80% basal insulin reduction applied 40 minutes before exercise onset (T-40)
Trial: 35099281
Drug: 80% basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80% basal insulin reduction applied 90 minutes before exercise onset (T-90)
Trial: 34283040
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam sedation
Trial: 34106628
Drug: Acupoint massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint massage combined with relaxation therapy
Trial: 32310620
Drug: linaclotide 145
RxNorm normalized name: LINACLOTIDE 145MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linaclotide 145 µg
Trial: 32310620
Drug: linaclotide 290
RxNorm normalized name: LINACLOTIDE 290MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linaclotide 290 µg
Trial: 36906404
Drug: IIV4-HD (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV4-HD (high-dose quadrivalent inactivated influenza vaccine) administered intramuscularly (IM)
Trial: 36906404
Drug: IIV4-SD (standard-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV4-SD (standard-dose influenza vaccine) administered subcutaneously (SC)
Trial: 36048453
Drug: modified FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified FOLFIRINOX (oxaliplatin, 85 mg/m2; irinotecan, 150-180 mg/m2; leucovorin, 400 mg/m2; fluorouracil, 2400 mg/m2, every 2 weeks)
Trial: 36048453
Drug: gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine (1000 mg/m2, days 1, 8, and 15, every 4 weeks)
Trial: 37435938
Drug: Insulin analogues
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin analogues
Trial: 35121633
Drug: Immediate smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate smoking cessation support with pharmacotherapy
Trial: 35570289
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual Optimized (TAU-O)
Trial: 33752741
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) 800/200 mg twice daily for 14 days
Trial: 34644618
Drug: Modified electroconvulsive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified electroconvulsive therapy (MECT)
Trial: 34644618
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (drugs alone)
Trial: 32302693
Drug: Febuxostat, 40
RxNorm normalized name: Febuxostat, 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat, 40 mg daily during acute gout attack
Trial: 32302693
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (febuxostat, 40 mg daily after attacks)
Trial: 34169339
Drug: Intraoperative norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative norepinephrine > 0.11 µg/kg/min
Trial: 33827126
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion rate of 0.1 μg/kg/min
Trial: 33827126
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion rate of 0.2 μg/kg/min
Trial: 33827126
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion rate of 0.4 μg/kg/min
Trial: 33827126
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia with 2% lidocaine containing 12.5 μg/mL epinephrine
Trial: 33827126
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (0.1, 0.2, 0.4 μg/kg/min)
Trial: 32265500
Drug: Dasatinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (100 mg)
Trial: 32265500
Drug: Imatinib (≥400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (≥400 mg)
Trial: 35101100
Drug: SBIRT (Screening,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBIRT (Screening, Brief Intervention, and Referral to Treatment)
Trial: 33692621
Drug: BreatheMate device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BreatheMate device with electronic reminders for budesonide/formoterol 160/4.5 μg twice daily
Trial: 33692621
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving the same medication without electronic reminders
Trial: 34855657
Drug: Diterpene ginkgolides
RxNorm normalized name: terpene resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diterpene ginkgolides meglumine injection (DGMI) 25 mg/d for 14 days
Trial: 36262727
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg nitroglycerine (Group N4)
Trial: 36262727
Drug: 800 μg
RxNorm normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 μg nitroglycerine (Group N8)
Trial: 32522503
Drug: Bitter-flavoured, 7.5mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitter-flavoured, 7.5mm film-coated tablets
Trial: 35188874
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D supplementation for 8 weeks along with conventional dry eye treatment (artificial tears)
Trial: 35188874
Drug: Conventional dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dry eye treatment (artificial tears) without vitamin D supplementation
Trial: 35546255
Drug: Intradermal hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal hepatitis B vaccine with topical imiquimod pre‐treatment (ID-Imq)
Trial: 35546255
Drug: Intramuscular hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular hepatitis B vaccine with aqueous cream pre‐treatment (IM-Aq)
Trial: 32246138
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cefotaxime (250 mg/kg/day) with oral acetaminophen (first dose 30 mg/kg, then 20 mg/kg every 6 hours)
Trial: 32246138
Drug: Cefotaxime conventionally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime conventionally as boluses (62.5 mg/kg, 4 times per day) with placebo orally
Trial: 32246138
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cefotaxime with oral acetaminophen
Trial: 33105394
Drug: DriSti intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DriSti intervention (2 sessions with videos and interactive exercises on a computer tablet and one interactive face-to-face group session)
Trial: 33106168
Drug: Placebo (288
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (288 mg of rice protein, 109.3 mg microcrystalline cellulose)
Trial: 35246395
Drug: Tianjiang Xueshuantong
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tianjiang Xueshuantong Wan pills
Trial: 35246395
Drug: rt‐PA intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt‐PA intravenous thrombolysis
Trial: 616861719
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg immunologically active gluten/d
Trial: 32191586
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1000 mg per day)
Trial: 33950234
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment for 1 year (n=19)
Trial: 33950234
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 1 year (n=18)
Trial: 35236649
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (benazepril hydrochloride tablets)
Trial: 33849341
Drug: Vascular-targeted photodynamic
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vascular-targeted photodynamic therapy (PDT)
Trial: 33849341
Drug: Salvage radical
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage radical prostatectomy (sRP) after focal therapy (FT)
Trial: 33849341
Drug: Salvage radical
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage radical prostatectomy (sRP) after radiation therapy (RT)